USD 0.0
(0.0%)
Year | Net Income | Net Income Growth |
---|---|---|
2021 | -56.51 Million USD | -411.47% |
2020 | -11.04 Million USD | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2022 Q2 | -10.73 Million USD | 24.54% |
2022 Q1 | -14.22 Million USD | 0.0% |
2021 FY | -56.51 Million USD | -411.47% |
2021 Q2 | -18.11 Million USD | 0.0% |
2020 FY | -11.04 Million USD | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
AstraZeneca PLC | 5.95 Billion USD | 100.949% |
Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | 100.704% |
CSPC Pharmaceutical Group Limited | 830.91 Million USD | 106.801% |
Novartis AG | 14.85 Billion USD | 100.381% |
PT Kalbe Farma Tbk. | 179.7 Million USD | 131.447% |